With the closing of our sixth fund at $900 million, we're excited to continue supporting pioneering technologies at the intersection of technology and biotech. Fund VI has invested in companies including Alumis, CG Oncology, Latigo Biotherapeutics, Inc., and Xaira Therapeutics. These companies are redefining what's possible in medicine; from novel treatments to cutting-edge technologies, their efforts are paving the way for a healthier future. We're inspired by the visionary entrepreneurs we work with and grateful for the continued support of our investors. Learn more about Fund VI via Michael Bodley for PitchBook.
Congratulations Vik Bajaj and Foresite Capital!
Congrats, Jim and team!
Chief Medical Officer | Research & Development Executive | Board-Certified Rheumatologist
1moCongratulations!